Metformin Hydrochloride/Sitagliptin Grindeks

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride/Sitagliptin Grindeks, is a biguanide presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus.

GNH USA supplies Metformin Hydrochloride/Sitagliptin Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride/Sitagliptin is indicated for the management of type 2 diabetes mellitus, targeting multiple pathways of glucose regulation.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels - Adjunct to diet and exercise in type 2 diabetes: enhances overall glycemic management - Combination therapy for inadequate control with monotherapy: provides additional glucose‑lowering effect

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea - Headache: mild to moderate intensity - Mild hypoglycemia: especially when used with other glucose‑lowering agents - Metallic taste: transient alteration in taste perception - Upper respiratory symptoms: nasopharyngitis or cough

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance - Severe hypoglycemia: profound low blood glucose requiring medical intervention - Pancreatitis: inflammation of the pancreas presenting with abdominal pain - Allergic reactions: rash, pruritus, or angioedema - Hepatic dysfunction: elevated liver enzymes or hepatitis - Stevens‑Johnson syndrome: rare severe skin reaction

Before initiating therapy, consider the following safety measures. - Renal function: assess baseline creatinine clearance and monitor periodically - Hepatic disease: use with caution in patients with liver impairment - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia or severe infection - Pregnancy: discuss potential risks and benefits with a healthcare professional - Concomitant sulfonylureas: monitor for enhanced hypoglycemia risk - Store at ambient temperature: keep in the original container, protect from moisture and heat

Metformin Hydrochloride/Sitagliptin may interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Renal‑impairing agents (e.g., iodinated contrast): increase risk of lactic acidosis - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise sitagliptin plasma concentrations - Excessive alcohol: potentiates lactic acidosis risk

Moderate Interactions (Monitor Closely): - Sulfonylureas: heightened hypoglycemia potential - Thiazolidinediones: additive risk of fluid retention and edema - Beta‑blockers: may mask hypoglycemia symptoms - Diuretics: can affect renal clearance of metformin - Anticoagulants (e.g., warfarin): monitor INR as metformin may alter its effect